Based at PhytoArk in Conthey, the start-up IBEX Therapeutics is reaching a new milestone in the development of its plant extract-based treatment for oral mucositis, a common complication caused by cancer treatment. Thanks to CHF 640,000 in funding granted by Innosuisse, the company is pursuing its research in collaboration with Geneva University Hospitals (HUG) and the HES-SO Valais-Wallis.
Founded in 2021, IBEX Therapeutics develops plant-based supportive therapies for oncology and oral diseases. Its main project aims to offer a new solution for oral mucositis, a painful inflammation of the oral mucous membrane that affects around 33,000 patients in Switzerland, and more than 780,000 across Europe every year.
This complication, mainly caused by radiotherapy and chemotherapy, can make eating difficult and lead to interruption in cancer care. Against the lack of effective treatments, IBEX Therapeutics is drawing on therapeutic properties of plants to develop a new approach.
Its treatment combines an exclusive extract of spear-leaved willowherb (Epilobium lanceolatum), a Swiss Alpine plant rich in oenothein B, with Aloe barbadensis. This combination is being studied for its anti-inflammatory, antioxidant, wound-healing, antibacterial and antifungal properties.
Two scientific collaborations to move the treatment forward
The CHF 640,000 in funding awarded by Innosuisse will enable IBEX Therapeutics to continue the preclinical and clinical validation of its treatment, in collaboration with two research institutes.
In collaboration with the Geneva University Hospitals (HUG), the company aims to collect clinical data on the safety and efficacy of its therapy. The research will focus on the progression of oral mucositis in patients suffering from head and neck cancers undergoing radiotherapy.
Simultaneously, a project conducted with the HES-SO Valais-Wallis aims to study the combined effects of the ingredients on the inflammation, bacteria and fungi, as well as their potential to restore the balance of the oral microbiome.
The results of these two collaborations could also lead to the filling of a new patent.
“This Innosuisse funding marks a milestone for IBEX Therapeutics and validates our approach following a highly rigorous and competitive evaluation process. It gives us the means to accelerate our development, to generate new preclinical and clinical data expected by investors, and bring our therapy to patients” says Pierre Morgon, CEO and co-founder of IBEX Therapeutics.
Further development milestones ahead
To pursue the development of its treatment, IBEX Therapeutics is currently seeking an additional CHF 800,000 in funding for the next two years. The aim is to carry the project forwards towards an agreement with a strategic partner responsible for its worldwide distribution.
Based at PhytoArk in Conthey, the start-up illustrates the potential of combining Alpine plant resources with scientific research in the healthcare sector.
Sources: IBEX Therapeutic’s press release and PhytoArk’s article
Image: IBEX Therapeutics
